Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.37 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.36 |
| ▸ | PGD | P52209 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.32 |
| ▸ | KDM4A | O75164 | 2/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.32 |
| ▸ | TET3 | O43151 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17867421 | 1.00 | PDE4A (0.56) | PDE4ATSHRCYP2C9USP2LMNA | |
| SCHEMBL14421374 | 1.00 | PDE4A (0.56) | PDE4ATSHRCYP2C9USP2LMNA | |
| SCHEMBL1895971 | 1.00 | PDE4A (0.56) | PDE4ATSHRCYP2C9USP2LMNA | |
| SCHEMBL10619545 | 0.93 | PDE4A (0.67) | PDE4ATSHRCYP2C9USP2LMNA | |
| SCHEMBL10619540 | 0.91 | PDE4A (0.64) | PDE4ATSHRCYP2C9USP2LMNA | |
| SCHEMBL2017250 | 0.86 | PDE4A (0.52) | PDE4ATSHRCYP2C9USP2LMNA | |
| SCHEMBL2784989 | 0.84 | PDE4A (0.48) | PDE4ATSHRCYP2C9USP2LMNA | |
| SCHEMBL3175311 | 0.82 | PDE4A (0.48) | PDE4ATSHRCYP2C9USP2LMNA | |
| SCHEMBL8984391 | 0.82 | PDE4A (0.48) | PDE4ATSHRCYP2C9USP2LMNA | |
| SCHEMBL7172292 | 0.82 | PDE4A (0.48) | PDE4ATSHRCYP2C9USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101365458-B | Methods and compositions for iron administration | LUITPOLD PHARM INC | 2012-09-05 | — | — | CN | claimed |
| CN-101365458-A | Methods and compositions for iron administration | LUITPOLD PHARM INC (US) | 2009-02-11 | — | — | CN | claimed |
| US-20250127925-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2025-04-24 | — | — | US | disclosed |
| US-12076418-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | ENGENE, INC. (CA) | 2024-09-03 | — | — | US | disclosed |
| CN-118103047-A | Iron compositions and methods of making and using the same | 美国瑞根特有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-117843818-A | Oxidation composition for dextrin oxidation and method for preparing carboxymaltodextrin | 金陵药业股份有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-113018256-B | Preparation process of ferric carboxymaltose injection | 金陵药业股份有限公司 | 2023-02-17 | — | — | CN | disclosed |
| CN-113018255-B | Preparation method of ferric carboxymaltose injection | 金陵药业股份有限公司 | 2023-02-17 | — | — | CN | disclosed |
| CN-115177625-A | Carboxyl ferric maltose pharmaceutical composition and preparation method thereof | 金陵药业股份有限公司 | 2022-10-14 | — | — | CN | disclosed |
| US-20220133907-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2022-05-05 | — | — | US | disclosed |
| EP-3970697-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | Engene, Inc. (CA) | 2022-03-23 | — | — | EP | disclosed |
| CN-101400380-B | Super-absorber having improved smell-inhibition, preparation method and uses | BASF SE | 2013-04-17 | — | — | CN | disclosed |
| CN-102947321-A | New low molecular weight complexes between iron and maltobionic acid, use thereof for intramuscular or subcutaneous administration in the treatment of anemic states, and new pharmaceutical compositions adapted for these uses | BIOFER SPA | 2013-02-27 | — | — | CN | disclosed |
| CN-101365458-B | Methods and compositions for iron administration | LUITPOLD PHARM INC | 2012-09-05 | — | — | CN | disclosed |
| CN-101407773-B | Pseudomonas putida GNA5 strain and method for preparing D-glucosamine acid by using same | NANJING UNIVERSITY OF TECHNOLOGY | 2010-11-03 | — | — | CN | disclosed |
| CN-101407773-A | Pseudomonas putida GNA5 strain and method for preparing D-glucosamine acid by using same | NANJING UNIVERSITY OF TECHNOLOGY (CN) | 2009-04-15 | — | — | CN | disclosed |
| CN-101400380-A | Super-absorber having improved smell-inhibition | BASF SE (DE) | 2009-04-01 | — | — | CN | disclosed |
| CN-101365458-A | Methods and compositions for iron administration | LUITPOLD PHARM INC (US) | 2009-02-11 | — | — | CN | disclosed |
| EP-1261611-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001064678-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127925-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | PDE4A 4587/4885TSHR 4331/4885CYP2C9 4006/4885 |
| US-12076418-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | CSGALNACT1, CHI3L2, LNPEP | PDE4A 4587/4885TSHR 4331/4885CYP2C9 4006/4885 |
| US-20220133907-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | PDE4A 4587/4885TSHR 4331/4885CYP2C9 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.